Showing results (61-70 of 721) with videos related to

Sort By:
Pageof 73
The Lancet. Haematology|October 7, 2018
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 studyFranco Locatelli, Christine Mauz-Koerholz, Kathleen Neville, et al.
The Lancet. Haematology|October 7, 2018
Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trialsBastian von Tresckow, Stefanie Kreissl, Helen Goergen, et al.
The Lancet. Haematology|October 7, 2018
Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trialNiels Wcj van de Donk, Bronno van der Holt, Monique C Minnema, et al.
The Lancet. Haematology|September 3, 2018
Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 studyHervé Tilly, Franck Morschhauser, Olivier Casasnovas, et al.
The Lancet. Haematology|May 29, 2019
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart dataMargarita Kushnir, Yun Choi, Ruth Eisenberg, et al.
The Lancet. Haematology|December 15, 2018
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trialNicholas J Short, Hagop M Kantarjian, Sanam Loghavi, et al.
The Lancet. Haematology|May 13, 2022
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trialMeletios A Dimopoulos, Paul G Richardson, Nizar J Bahlis, et al.
The Lancet. Haematology|February 4, 2018
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre studyPaul M Barr, Hongli Li, W Richard Burack, et al.
The Lancet. Haematology|March 19, 2018
Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trialMaro Ohanian, Ana Tari Ashizawa, Guillermo Garcia-Manero, et al.
The Lancet. Haematology|March 19, 2018
Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trialFrederick Fasslrinner, Johannes Schetelig, Andreas Burchert, et al.
Pageof 73